[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anoca---angina-with-non-obstructive-coronary-arteries\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anoca---angina-with-non-obstructive-coronary-arteries":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,76,98,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639304","invasive-evaluation-and-phenotype-guided-treatment-of-anoca-in-women-100639304",false,"NCT07593157","Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women","Invasive Functional and Morphological Coronary Assessment Followed by Phenotype-Guided Multidisciplinary Treatment in Women With Angina and Non-Obstructive Coronary Arteries: A Prospective Single-Center Interventional Study","ANOCA-UY","Inclusion Criteria:\n\n* Female participants aged 35 to 75 years.\n* Symptoms compatible with stable angina or suspected myocardial ischemia.\n* Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%.\n* Ability to undergo invasive coronary assessment and clinical follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Significant structural heart disease.\n* Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \\\u003C40%.\n* Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity.\n* Active oncological disease or life expectancy less than 12 months.\n* Inability to complete the diagnostic or therapeutic study protocol.\n* Participation in another clinical study that could interfere with the present protocol.","FEMALE","35 Years","75 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology, acetylcholine provocation testing, and optical coherence tomography. The diagnostic protocol will identify functional and morphological mechanisms of angina, including microvascular dysfunction, epicardial vasospasm, microvascular spasm, endothelial dysfunction, functional epicardial disease, combined mechanisms, or normal coronary physiology.\n\nBased on the identified phenotype, participants will receive individualized multidisciplinary treatment, including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when indicated. Clinical follow-up will be performed at 1, 6, and 12 months to assess angina symptoms, quality of life, functional capacity, adherence to treatment, and cardiovascular events.",[28,29,30],"ANOCA - Angina With Non-obstructive Coronary Arteries","Coronary Microvascular Dysfunction (CMD)","Vasospastic Angina",[32,33,34,35,36],"Angina with non-obstructive coronary arteries","ANOCA","INOCA","Vasospastic angina","Coronary Microvascular Dysfunction","NOT_YET_RECRUITING","2026-05-15",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":38,"type":22},{"date":44,"type":22},"2029-04-30",{"name":46,"class":47},"Hospital de Clínicas Dr. Manuel Quintela","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100585018","analysis-of-coronary-reactivity-testing-with-and-without-intracoronary-nitrate-testing-100585018","NCT06896903","Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing","CRT-NITRO","Inclusion Criteria:\n\n1. Aged 18 or older\n2. Patient being evaluated for ANOCA or INOCA\n3. Clinical suspicion for angina\n4. Patient should be able to comply with the protocol.\n5. Provide written informed consent before study participation.\n\nExclusion Criteria:\n\n1. Existing coronary artery disease\n2. Previous percutaneous interventions within the coronaries\n3. Current use (within 48 hours) of long-acting nitrate therapies\n4. Current use (within 48 hours) of PDE-5 inhibitors (sildenafil, tadalafil)\n5. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study.\n6. Children below 18 years, prisoners, pregnant people and patients who are unable to provide consent are excluded.","ALL","18 Years",{"count":21,"type":22},[25],"This single-arm, multi-center, prospective study will assess the coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and determinants thereof (transit time, Pa, Pd) in patients before and after intracoronary nitroglycerine.",[28,62],"INOCA (Ischemia With Non Obstructive Coronary Artery Disease)",[64,65],"Coronary Reactivity Testing","Intracoronary Nitroglycerine","RECRUITING","2026-04-30",{"date":69,"type":41},"2026-05-05",{"date":71,"type":41},"2025-05-21",{"date":73,"type":22},"2027-06-01",{"name":75,"class":47},"Baylor Research Institute",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100625452","non-invasive-evaluation-of-patients-with-angina-and-non-obstructive-coronary-artery-disease-100625452","NCT07422818","Non-invasive Evaluation of Patients With Angina and Non-obstructive Coronary Artery Disease","NEO-NOCAD","Inclusion Criteria:\n\n1. Age between 18 and 90 years;\n2. ICA performed within the previous 12 months from enrollment and characterized by: (a) absence of obstructive CAD (\\<50% diameter reduction or FFR by \\>0.80); (b) invasive assessment of epicardial\u002Fmicrovascular spasm by acetylcholine test;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Presentation as an acute coronary syndrome (i.e. unstable chest pain) or a typical history of variant angina (frequent angina pain at rest with ST-segment elevation at the ECG, caused by recurrent coronary spasm);\n2. Previous coronary revascularization with surgical intervention;\n3. Asthma or known intolerance or contraindications to dipyridamole;\n4. Serious medical conditions, including renal failure (eGFR \\<30 mL\u002Fmin), liver diseases, malignancies, and acute or chronic inflammatory diseases;\n5. Pregnancy;\n6. Psychological conditions that might hamper patient co-operation;\n7. Any condition that, in the judgment of the investigators, would make difficult for the patient to complete the study protocol;\n8. Missed informed consent.",true,{"count":85,"type":22},35,[25],"This is a single-center, prospective interventional study evaluating noninvasive coronary function testing using transthoracic Doppler echocardiography of the left anterior descending coronary artery in patients with stable angina and nonobstructive coronary artery disease (ANOCA) who previously underwent invasive coronary function testing (adenosine and\u002For acetylcholine).\n\nA group of age- and sex-matched healthy volunteers will be enrolled to support interpretation of potentially abnormal noninvasive responses observed in patients.",[28],"2026-02-13",{"date":91,"type":41},"2026-02-20",{"date":93,"type":22},"2026-03",{"date":95,"type":22},"2026-11",{"name":97,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":106,"targetDuration":108,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":48},"100600886","comprehensive-coronary-physiology-in-patients-with-angina-with-nonobstructive-coronary-arteries---czech-republic-100600886","NCT07103317","Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","Comprehensive COROnary PHYSiology Assessment in Patients With Angina With Nonobstructive Coronary Arteries - CZECH Republic (CoroPhys-CZECH)","CoroPhys-CZ","Inclusion Criteria:\n\n* Adults of both sexes older than 18 years\n* Angina symptoms or angina equivalent\n* Referred to cath lab for evaluation of CAD\n* Invasive physiology testing performed (microcirculation testing +\u002F- vasospasm testing)\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Pregnant of nursing\n* No coronary physiology measurements were performed",{"count":107,"type":22},1000,"100 Years","OBSERVATIONAL","Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of microcirculation and vasospastic disorders in causing angina. The microvascular bed is composed of vessels smaller than 400 microns in diameter. Their network is significantly larger than that of the epicardial vessels and serves essential functions, including regulating myocardial blood flow and cellular metabolism.\n\nAngina pectoris, a most frequent symptom of CAD or myocardial ischemia, was assumed to be caused by significant stenosis of the epicardial coronary artery. However, it was found that in over 50% of cases, there was no obstructive CAD, which is described as angina with no obstructive coronary arteries (ANOCA) or ischemia with no obstructive coronary arteries (INOCA), according to the clinical setting.",[33,28,112,113,114,30,115],"MINOCA","Microvascular Dysfunction","Microvascular Angina","Acetylcholine",[33,34,112,36,114,30,117,118],"Acetylcholine Testing","Coronary Termodilution","2025-08-01",{"date":121,"type":41},"2025-08-05",{"date":123,"type":41},"2023-04-20",{"date":125,"type":22},"2030-01-01",{"name":127,"class":47},"University Hospital, Motol",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100574170","phase-3-nebivolol-anoca-treatment-randomized-trial-100574170","NCT06755801","Nebivolol ANOCA Treatment Randomized Trial","Microvascular Obstruction Treatment and Outcomes Randomized Study.","MOTORS","Inclusion Criteria:\n\n* Age 18 years or older.\n\n  * Presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months.\n  * Absence of functionally significant epicardial coronary artery disease (FFR \\> 0.80).\n  * Microvascular functional study showing CFR\\\u003C 2,0 and\u002For IMR ≥ 25.\n\nExclusion Criteria:\n\n* Allergy or contraindication to the use of beta-blockers.\n* Indication for beta-blocker treatment due to another pathology.\n* Ventricular dysfunction (LVEF \\\u003C 45%).\n* Percutaneous coronary revascularization in the last 6 months.\n* History of surgical revascularization.\n* First-degree atrioventricular block or bifascicular block.\n* Presence of hemodynamically significant valvulopathy.\n* Presence of cardiomyopathy or congenital cardiac anomaly.\n* Severe renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin).\n* Liver failure (history of cirrhosis or transaminase elevation \\> 3 times the upper limit of normal).\n* Pregnant or lactating women.",{"count":137,"type":22},150,[139],"PHASE3","To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.",[28,29],[143,144,145],"Coronary Microvascular Disease","Betablockers","Angina","2024-12-31",{"date":148,"type":41},"2025-01-01",{"date":150,"type":22},"2025-04-01",{"date":152,"type":22},"2026-09-30",{"name":154,"class":47},"Spanish Society of Cardiology"]